12-Month Multicenter Outcomes Of Third-Generation Trabecular Micro-Bypass Stents In Eyes With Open-Angle Glaucoma
Published 2025 - 43rd Congress of the ESCRS
Reference: FP08.08 | Type: Free paper | DOI: 10.82333/ap40-d088
Authors: Clemens Strohmaier* 1 , Martin Kallab 1 , Isabella Vieböck 1 , Kaweh Mansouri 2 , Alex Huang 3 , Matthias Bolz 1
1Ophthalmology/Optometry,Johannes Kepler University,Linz,Austria, 2Ophthalmology,Montchoisi Clinique,Lausanne,Switzerland, 3Shiley Eye Institute/Viterbi Familiy Department of Ophthalmology,University of California,San Diego,United States
Purpose
The current multicenter study assessed efficacy and safety of iStent infinite implantation with or without
cataract surgery in patients with open-angle glaucoma.
Setting
Surgeries were performed by 7 glaucoma surgeons at 6 sites in the United States.
Methods
This multicenter, retrospective, real-world case series included 64 eyes with open-angle glaucoma who
underwent implantation of the third-generation trabecular micro-bypass stent (iStent infinite,
containing three stents) with or without cataract surgery. No preoperative medication washout was
conducted. In the consistent cohort of eyes with 12-month data, intraocular pressure (IOP) and topical
IOP-lowering medications prior to iStent infinite implantation were compared to IOP and topical IOP-
lowering medications 12 months post-operatively. Safety parameters and incidence of secondary
procedures were also recorded. Additional patients with 12-month follow-up will be added by the time
of the conference.
Results
All patients underwent successful implantation of 3 iStent infinite stents. In the consistent cohort of
eyes with 12 month data (n=64 eyes), mean IOP reduced from 18.1±3.7 mmHg preoperatively to
13.8±3.2 mmHg at month 12 (23% reduction, P=0.001). Mean number of medications reduced from
1.31±0.87 preoperatively to 0.64±1.00 at month 12 (51% reduction, P=0.001). 43/64 eyes (67%)
achieved an IOP ≤14mmHg at month 12, and 23/64 eyes (36%) achieved an IOP ≤12mmHg at month 12.
Twelve months following implantation, 39/64 eyes (61%) were free of topical IOP lowering medications
versus 5/64 eyes (8%) pre-implantation. No intraoperative complications were reported. AEs were mild
and resolved without sequelae after the immediate postoperative period.
Conclusions
Implantation of iStent infinite with or without cataract surgery in patients with open-angle glaucoma
yielded statistically significant and clinically meaningful IOP and topical medication reductions in this
multicenter, U.S. based, retrospective, real-world case series.